PURPOSE: To determine the optimal phase for enhancement of the normal pancreas and peripancreatic vasculature and the maximal @entity5 -to-pancreatic parenchymal enhancement difference by using multiphase, contrast material-enhanced, multi-detector row helical computed tomography (CT). MATERIALS AND METHODS: Forty-nine @entity1 with a normal-appearing pancreas but suspected of having @entity660 and 28 @entity1 with proved @entity788 underwent multiphase, contrast-enhanced, multi-detector row CT during the arterial phase (AP), pancreatic parenchymal phase (PPP), and portal venous phase ( @entity12468 ). Attenuation values of the normal pancreas, @entity788 , celiac and superior mesenteric arteries, and superior mesenteric and portal veins were measured during all three imaging phases. Quantitative analysis of these measurements and subjective qualitative analysis of @entity5 conspicuity were performed. RESULTS: Maximal enhancement of the normal pancreatic parenchyma occurred during the PPP. @entity5 attenuation differences during the PPP and @entity12468 were equivalent but greater than that during the AP. Subjective analysis revealed that @entity5 conspicuity during the PPP and @entity12468 was equivalent but superior to that during the AP. Maximal arterial enhancement was seen during the PPP, and maximal venous enhancement was seen during the @entity12468 . CONCLUSION: A combination of PPP and @entity12468 imaging is sufficient for detection of @entity788 , because it provides maximal pancreatic parenchymal and peripancreatic vascular enhancement. AP imaging can be reserved for @entity1 in whom CT angiography is required.

Multi--detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic adenocarcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Maximal tumor-to-parenchyma'] @entity660 :: ('MESH:D010182', 'Disease') :: ['pancreatic abnormality'] @entity12468 :: ('CHEBI:53245', 'Chemical') :: ['PVP']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']
